Viatris Inc. announced that it will be acquiring both Oyster Point Pharma and Famy Life Sciences, which will help the company meet its goal of creating an ophthalmology franchise, according to a press release.
“These acquisitions bring us an innovative growth asset, Tyrvaya, and five additional phase III or phase III-ready programs that give us a significant head-start in creating a leading ophthalmology franchise," Michael Goettler, CEO of Viatris, said in the release.
The franchise will reportedly function as a separate division within Viatris and will be led by Oyster (Read more...)